Marcel R.M. van den Brink, MD, PhD

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, discusses two abstracts being presented at ASH looking at CAR T cell therapies for the treatment of ALL and NHL.

Marcel R.M. van den Brink, MD, PhD, from Memorial Sloan Kettering Cancer Center, describes a novel CLIA-certified next-generation sequencing-based assay for hematologic malignancies.

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, highlights two studies that will be presented at the 2013 American Society of Hematology (ASH) Meeting.